SpectraCure (Sweden) Today
| SPEC Stock | SEK 1.94 0.15 8.38% |
PerformanceVery Weak
| Odds Of DistressAbout Average
|
SpectraCure is selling for under 1.94 as of the 19th of March 2025; that is 8.38 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.71. SpectraCure has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Moving against SpectraCure Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
SpectraCure Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. SpectraCure's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding SpectraCure or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Medical Devices, Healthcare (View all Sectors) |
SpectraCure AB (SPEC) is traded on Stockholm Exchange in Sweden and employs 15 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 565.68 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate SpectraCure's market, we take the total number of its shares issued and multiply it by SpectraCure's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. SpectraCure AB operates under Healthcare sector and is part of Medical Devices industry. The entity has 97.13 M outstanding shares.
SpectraCure AB has accumulated about 129.69 M in cash with (18.6 M) of positive cash flow from operations.
Check SpectraCure Probability Of Bankruptcy
Ownership AllocationSpectraCure AB shows a total of 97.13 Million outstanding shares. SpectraCure AB maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check SpectraCure Ownership Details
SpectraCure AB Risk Profiles
Although SpectraCure's alpha and beta are two of the key measurements used to evaluate SpectraCure's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 5.49 | |||
| Standard Deviation | 8.31 | |||
| Variance | 69.01 | |||
| Risk Adjusted Performance | (0.07) |
SpectraCure Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in SpectraCure without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
SpectraCure Corporate Management
Elected by the shareholders, the SpectraCure's board of directors comprises two types of representatives: SpectraCure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SpectraCure. The board's role is to monitor SpectraCure's management team and ensure that shareholders' interests are well served. SpectraCure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SpectraCure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mirjam Johansson | Adm Mang | Profile | |
| Kristina Holst | Head Affairs | Profile | |
| Henrik Ljung | Chief Officer | Profile | |
| Johannes Swartling | Technical Mang | Profile | |
| Johan Folkunger | Chief Officer | Profile |
Additional Tools for SpectraCure Stock Analysis
When running SpectraCure's price analysis, check to measure SpectraCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpectraCure is operating at the current time. Most of SpectraCure's value examination focuses on studying past and present price action to predict the probability of SpectraCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpectraCure's price. Additionally, you may evaluate how the addition of SpectraCure to your portfolios can decrease your overall portfolio volatility.